Analysts expect Clene Inc. (NASDAQ:CLNN – Get Rating) to report ($0.18) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Clene’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.18). Clene reported earnings per share of ($0.19) in the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Clene will report full year earnings of ($0.71) per share for the current financial year, with EPS estimates ranging from ($0.75) to ($0.68). For the next financial year, analysts forecast that the company will report earnings of $0.04 per share. Zacks’ EPS calculations are an average based on a survey of research firms that follow Clene.
Clene (NASDAQ:CLNN – Get Rating) last issued its quarterly earnings data on Friday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23.
In other news, Director David J. Matlin acquired 10,000 shares of Clene stock in a transaction on Monday, March 28th. The stock was acquired at an average cost of $3.10 per share, with a total value of $31,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David J. Matlin acquired 20,000 shares of Clene stock in a transaction on Friday, March 18th. The shares were purchased at an average cost of $2.79 per share, with a total value of $55,800.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 319,243 shares of company stock worth $947,104. Insiders own 28.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in CLNN. Morgan Stanley grew its holdings in Clene by 110.5% during the first quarter. Morgan Stanley now owns 2,105 shares of the company’s stock valued at $27,000 after purchasing an additional 1,105 shares during the period. Bank of America Corp DE grew its holdings in Clene by 7,045.1% during the second quarter. Bank of America Corp DE now owns 5,859 shares of the company’s stock valued at $66,000 after purchasing an additional 5,777 shares during the period. Wells Fargo & Company MN grew its holdings in Clene by 9,823.7% during the second quarter. Wells Fargo & Company MN now owns 13,000 shares of the company’s stock valued at $146,000 after purchasing an additional 12,869 shares during the period. Soltis Investment Advisors LLC bought a new position in Clene during the third quarter valued at $1,495,000. Finally, Morgan Jess S & Co. Inc. bought a new position in Clene during the third quarter valued at $203,000. 15.24% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ CLNN traded down $0.10 during mid-day trading on Wednesday, reaching $2.90. 74,464 shares of the company’s stock traded hands, compared to its average volume of 110,348. The company has a debt-to-equity ratio of 1.52, a current ratio of 9.06 and a quick ratio of 9.05. The business has a 50-day simple moving average of $3.06 and a 200 day simple moving average of $3.97. Clene has a 1-year low of $2.36 and a 1-year high of $17.82. The stock has a market cap of $183.42 million, a P/E ratio of -13.18 and a beta of 0.11.
About Clene (Get Rating)
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
- Get a free copy of the StockNews.com research report on Clene (CLNN)
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.